LUCD News and Press, Lucid Diagnostics Inc. From 03/25/24

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results PR Newswire Quarterly EsoGuard ® revenue increased 33 percent sequentially Expanding EsoGuard clinical validity and clinical utility data poised to d...

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative ...

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference PR Newswire Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophage...

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , March 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Luci...

Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...

Lucid Diagnostics Provides Update Regarding World Trade Center Health Program PR Newswire NEW YORK , Feb. 16, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and ...

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Tes...

Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors PR Newswire The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participant...

2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies PR Newswire Studies demonstrate real-world clinical utility of EsoGuard testing to detect esophageal precancer NEW YORK , Dec. 12, 2023 /PRNewswi...